Core Viewpoint - Recently, Ganli Pharmaceutical (603087) announced the approval of its insulin glargine injection and pre-filled pen by the Ethiopian National Food and Drug Administration, marking a significant opportunity for the company in the Ethiopian market [1] Company Summary - The insulin glargine product is designed for diabetes patients, characterized by long-acting and stable blood sugar control, requiring subcutaneous injection once daily with a duration of action lasting up to 24 hours [1] - As of September 30, 2025, the company has invested a total of 936 million RMB in research and development for the insulin glargine project [1] Industry Summary - According to the International Diabetes Federation, the estimated number of diabetes patients aged 20-79 in Ethiopia is approximately 2.3 million, with a diabetes prevalence rate of 3.6% in 2024 [1] - While the approval of the drug registration provides a sales opportunity in the Ethiopian market, the company faces uncertainties related to market demand fluctuations, policy environment changes, and exchange rate volatility [1]

Group 1 - The company, Ganli Pharmaceutical Co., Ltd., has received approval from the Ethiopian Food and Drug Authority for the registration of its insulin glargine injection and pre-filled pen, indicating a significant step in its market expansion in Ethiopia [1][2] - The approved drug, BasalinTM, is indicated for diabetes treatment and is available in two forms: injection and pre-filled pen, both with a concentration of 100 units/ml in a 3ml vial [1] - The insulin glargine is a long-acting insulin that requires daily subcutaneous injection, providing a stable blood glucose level for up to 24 hours [1] Group 2 - Ethiopia has a population of approximately 130 million, with a projected diabetes patient population of around 2.3 million among individuals aged 20-79, representing a prevalence rate of 3.6% [2] - The average annual expenditure on diabetes-related healthcare per patient in Ethiopia is estimated at $96.2 [2] - Sanofi is currently the main supplier of insulin glargine in Ethiopia, with global sales of its insulin products projected to reach €2.855 billion (approximately $2.989 billion) in 2024 [2] Group 3 - As of September 30, 2025, the company has invested a total of 936 million RMB in research and development for the insulin glargine project [3]

Core Viewpoint - Ganli Pharmaceutical has received approval from the Ethiopian Food and Drug Authority for its insulin products, indicating a significant step in expanding its market presence in Ethiopia [1]. Group 1 - The company announced the receipt of registration certificates for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen [1]. - The registration numbers for the products are 11865/13208/NMR/2025 and 11864/13210/NMR/2025, respectively [1].

Core Viewpoint - Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, marking a significant milestone for the company in expanding its market presence in the region [1]. Company Summary - Ganli Pharmaceutical (603087) announced on January 15 that it has obtained the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1]. - The approved Glargine Insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a sustained hypoglycemic effect for 24 hours [1]. - The characteristics of Glargine Insulin include a long duration of action, stable blood concentration without peaks, and smooth glucose control [1].

Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Group 1 - The core point of the article is that Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, which is a significant milestone for the company [1] Group 2 - Ganli Pharmaceutical announced on January 15 that it received the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1] - Glargine insulin is a long-acting insulin that is injected subcutaneously once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1] - The characteristics of Glargine insulin include a long duration of action, stable blood concentration without peaks, and smooth blood sugar control [1]

一、药物基本情况 1、药品名称：Basalin TM 甘李药业股份有限公司 关于甘精胰岛素注射液及其预填充注射笔获得埃塞 俄比亚药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，甘李药业股份有限公司（以下简称"公司"、"甘李药业"）收到埃 塞俄比亚国家食品药品监督管理局（Ethiopian Food and Drug Authority）核准签 发的甘精胰岛素注射液及甘精胰岛素注射液预填充注射笔注册批件（批件号： 11865/13208/NMR/2025、11864/13210/NMR/2025）。现将相关情况公告如下： 证券代码：603087 证券简称：甘李药业 公告编号：2026-005 2、药品通用名：甘精胰岛素注射液、甘精胰岛素注射液预填充注射笔 3、适应症：糖尿病 4、剂型：注射剂 5、规格：3ml：100 units/ml（卡式瓶）、3ml：100 units/ml（预填充注射笔） 6、批件号：11865/13208/NMR/2025、11864/13210/NMR/2025 7、申请人：甘 ...

Core Viewpoint - The company has received regulatory approval from the Ethiopian National Food and Drug Administration for its insulin products, indicating a significant step in expanding its market presence in Ethiopia [1] Group 1: Product Approval - The company announced the approval of its Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen registration certificates [1] - The product is named BasalinTM, indicated for diabetes treatment, and is available in two forms: 3ml at 100 units/ml in vial and 3ml at 100 units/ml in pre-filled pen [1] - Glargine insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1]

Core Viewpoint - Gan Li Pharmaceutical has received approval from the Ethiopian Food and Drug Authority for the registration of Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen, indicating a significant step in expanding its product offerings in the Ethiopian market [1] Company Summary - The approved products include Glargine Insulin Injection and its pre-filled pen, with registration numbers 11865/13208/NMR/2025 and 11864/13210/NMR/2025 respectively [1] - Glargine Insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1] - The characteristics of Glargine Insulin include a long duration of action, stable blood concentration without peaks, and smooth glucose control [1]

此次获批标志着甘李药业的甘精胰岛素注射液正式进入欧洲市场，将在欧盟（EU）、冰岛、列支敦士 登和挪威上市销售。 近日，甘李药业（603087）发布公告称，公司及其欧洲全资子公司宣布，由甘李药业自主研发的甘精胰 岛素注射液（欧盟商品名：Ondibta ，中国商品名：长秀霖 1），于近日获得欧盟委员会（EC）批准， 用于治疗成人、青少年和2岁及以上儿童的糖尿病。 ...